Skip to content

A Trial to Study the Effect of Vitamin D Supplementation on Glucose and Insulin Metabolism in Centrally Obese Men

A Double Blind Randomized Control Trial to Study the Effect of Vitamin D Supplementation on Peripheral Insulin Sensitivity in Centrally Obese Men

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00347542
Enrollment
100
Registered
2006-07-04
Start date
2006-07-31
Completion date
2007-10-31
Last updated
2013-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Non-Insulin-Dependent, Obesity

Keywords

Vitamin D, Diabetes, Insulin sensitivity, Obesity

Brief summary

The purpose of the study is to evaluate the change in glucose and insulin metabolism(early markers for development of diabetes) after 6 weeks of weekly Vitamin D supplementation. As vitamin D has been reported to be associated with lipid levels, CRP and blood pressure , we will also be measuring the changes in these variables.

Detailed description

Accumulating evidence suggests that serum Vitamin D levels may be inversely related to the prevalence of diabetes, to the concentration of glucose , insulin resistance and metabolic syndrome.These results have been replicated in patients at risk for diabetes with documentation of impairment in insulin secretion in Vitamin D deficient subjects. Therefore, vitamin D could be implicated in the pathogenesis of type 2 diabetes, by affecting either insulin sensitivity or ß cell function, or both. However, there is paucity of literature on the effect of Vitamin D supplementation on insulin resistance or glucose metabolism. As vitamin D has been reported to be associated with lipid levels, CRP and blood pressure , we will also be measuring the changes in these variables.

Interventions

DRUGVitamin D

Sponsors

Sitaram Bhartia Institute of Science and Research
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE

Eligibility

Sex/Gender
MALE
Age
35 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Male * ≥35 years of age * Waist circumference ≥78 cm

Exclusion criteria

* Diabetic- Fasting Blood Sugar \>126 mg/dl or on anti-diabetic medication * BP\>140/90 or on anti-hypertensive medication * Receiving Vitamin D or calcium supplementation * Chronic disease-renal/hepatic/malignancy/gastrointestinal * On any medication within the last one month which could potentially influence insulin secretion, insulin sensitivity, Vitamin D or Calcium metabolism * Febrile illness or infective morbidity in the past 10 days * Past history of nephrolithiasis

Design outcomes

Primary

MeasureTime frame
Oral Glucose Insulin Sensitivity (OGIS)

Secondary

MeasureTime frame
Lipid profile
CRP
ApoA1
ApoB
Blood Pressure

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026